News - North America, Eli Lilly

Filter

Current filters:

North AmericaEli Lilly

Popular Filters

1 to 25 of 44 results

NDA filing for empagliflozin and linagliptin combo accepted by FDA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

14-04-2014

The US Food and Drug Administration has accepted the filing of the New Drug Application for the investigational…

Boehringer IngelheimDiabetesEli LillyempagliflozinJardiancelinagliptinNorth AmericaPharmaceuticalRegulationTradjentaUSA

Prasco to market the authorized generic of Lilly’s Evista in USA

01-04-2014

Privately-held US generics firm Prasco has signed a further deal with US pharma major Eli Lilly to market…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsMarkets & MarketingNorth AmericaPrasco LaboratoriesUSA

Lilly's Alimta patent upheld through 2022

Lilly's Alimta patent upheld through 2022

01-04-2014

US pharma major Eli Lilly says that the US District Court for the Southern District of Indiana has ruled…

AlimtaEli LillyLegalNorth AmericaOncologyPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

05-03-2014

There was disappointment today for US drug major Eli Lilly and family-owned German pharma firm Boehringer…

Boehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaPharmaceuticalProductionRegulationUSA

Teva gains approval for generic Evista in the USA

Teva gains approval for generic Evista in the USA

04-03-2014

Israel-based Teva Pharmaceutical Industries says it has received approval from the US Food and Drug Administration…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsNorth AmericaRegulationTeva Pharmaceutical IndustriesUSA

FDA investigating risk of stroke, heart attack and death with testosterone products

FDA investigating risk of stroke, heart attack and death with testosterone products

03-02-2014

The US Food and Drug Administration said on Friday that it is investigating the risk of stroke, heart…

AbbVieActavisAndrodermAndroGelAxironEli LillyMen's HealthNorth AmericaPharmaceuticalRegulationResearchTestosteroneUSA

Sanofi sues Eli Lilly over Lantus patent infringement

Sanofi sues Eli Lilly over Lantus patent infringement

31-01-2014

French drug major Sanofi says it has filed a patent infringement suit against USA pharma firm Eli Lilly…

BiosimilarsDiabetesEli LillyLantusLegalNorth AmericaPatentsPharmaceuticalSanofiUSA

Actavis confirms challenge of Lilly’s Axiron patent

Actavis confirms challenge of Lilly’s Axiron patent

14-11-2013

US generics major Actavis confirms that it has filed an Abbreviated New Drug Application with the US…

ActavisAxironEli LillyGenericsLegalMen's HealthNorth AmericaPatentsRegulation

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients

07-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Through 2022, growth in the neuropathic pain drug market will be constrained by generics

05-11-2013

The loss of US and European market exclusivity of three sales-leading neuropathic pain (NP) agents -…

Asia-PacificCymbaltaEli LillyEndo PharmaceuticalsEuropeLidodermLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Type 2 diabetes market to reach $38.8 billion by 2019

25-10-2013

The global type 2 diabetes market is expected to expand from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

Eli Lilly exceeds expectations with third quarter results

Eli Lilly exceeds expectations with third quarter results

24-10-2013

US pharma major Eli Lilly has announced financial results for the third quarter of 2013. Despite the…

AlimtaAmyvidAxironCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraTrajentaZyprexa

Lilly reveals strong pipeline as it seeks to recover from reaching patent cliff

Lilly reveals strong pipeline as it seeks to recover from reaching patent cliff

04-10-2013

Eli Lilly hopes to launch new medicines to treat unmet patient needs in an aim to return the company…

Eli LillyFinancialNorth AmericaPharmaceutical

Mixed Phase III results with Lilly’s ramucirumab

Mixed Phase III results with Lilly’s ramucirumab

26-09-2013

US drug major Eli Lilly has announced top-line results from a global Phase III study of ramucirumab in…

Eli LillyNorth AmericaOncologyPharmaceuticalramucirumabResearch

Global type 2 diabetes market to reach $38.8 billion by 2019

25-09-2013

The global type 2 diabetes market is expected to grow from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinLG Life SciencesMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

Novo Nordisk falls on loss of two US contracts

04-09-2013

Danish insulin giant Novo Nordisk (NOV: N) saw its shares fall 2.8% to 936 Danish kroner yesterday (September…

Bristol-Myers SquibbDiabetesEli LillyMarkets & MarketingNorth AmericaNovo NordiskNovoLogPharmaceuticalVictoza

Eli Lilly records higher than expected earnings in 2nd-qtr results

24-07-2013

US drug major Eli Lilly's (NYSE: LLY) recorded higher than expected earnings as growth in key products…

AlimtaCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraZyprexa

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Pivotal drivers for prescribing metastatic pancreatic cancer drugs: report

09-07-2013

The effect on key efficacy endpoints, primarily the effect of an emerging therapy on overall survival,…

AbraxaneBiotechnologyCelgeneEli LillyEuropeGemzarMarkets & MarketingNorth AmericaOncologyOnconova TherapeuticsPharmaceuticalrigosertib

FDA approves Boehringer and Lilly's Tradjenta and Jentadueto labeling to reflect pancreatitis risk

21-06-2013

German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) revealed yesterday (June…

Boehringer IngelheimDiabetesEli LillyJentaduetoNorth AmericaPharmaceuticalRegulationTradjenta

FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv

19-06-2013

The US Food and Drug Administration yesterday (June 18) revealed it is investigating two unexplained…

Eli LillyNeurologicalNorth AmericaPharmaceuticalRegulationZyprexa

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

1 to 25 of 44 results

Back to top